表紙
市場調査レポート

世界における子宮内膜症市場

Global Endometriosis Market 2014-2018

発行 TechNavio (Infiniti Research Ltd.) 商品コード 274379
出版日 ページ情報 英文 79 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.02円で換算しております。
Back to Top
世界における子宮内膜症市場 Global Endometriosis Market 2014-2018
出版日: 2014年06月30日 ページ情報: 英文 79 Pages
概要

世界の子宮内膜症市場は、2013年から2018年にかけて、2.86%の複合年間成長率(CAGR)で拡大する見込みです。

当レポートでは、世界における子宮内膜症市場の動向と将来の成長見通し、主要ベンダーの情報などを提供しています。

第1章 エグゼクティブサマリー

第2章 略語リスト

第3章 調査範囲

  • 市場概要
  • 主な製品
    • 製品プロファイル

第4章 市場調査手法

  • 市場調査プロセス
  • 調査手法

第5章 イントロダクション

第6章 市場情勢

  • 市場概要
  • 市場規模と予測
  • ファイブフォース分析

第7章 罹患率と有病率

第8章 治療タイプ別の市場区分

  • ホルモン治療
  • 鎮痛剤

第9章 投与経路および剤形別の市場区分

  • 経口
  • 非経口
  • 局所

第10章 パイプラインポートフォリオ

第11章 地理区分

第12章 購入基準

第13章 市場成長因子

第14章 成長因子とその影響

第15章 市場の課題

第16章 成長因子と課題の影響

第17章 市場動向

第18章 動向とその影響

第19章 ベンダー情勢

  • 競合シナリオ
    • 主なニュース
  • 市場シェア分析
  • その他のベンダー

第20章 主要ベンダーの分析

  • AbbVie Inc.
  • AstraZeneca plc
  • Bayer AG
  • Pfizer Inc.

第21章 関連レポート

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: IRTNTR3730

About Endometriosis

Endometriosis is a common female health condition where the endometrial tissue, which is usually found inside the lining of the uterus, appear and grows outside the uterine cavity. Endometriosis mostly occurs in the fallopian tubes, ovaries, outer surface of the uterus, pelvic cavity, vagina, cervix, and bladder. Endometriosis has rarely been reported in more distant parts of the body such as the lungs, brain, and skin. The most common symptoms associated with endometriosis are pelvic pain, dysmenorrhea, excessive bleeding, and lower abdominal pain. Some of the uncommon symptoms of endometriosis are rectal bleeding and hematuria. The detection of endometriosis in women is difficult because of the common symptoms associated with it. Endometriosis can be diagnosed by laparoscopy, ultrasound, pelvic exam, and biopsy of the inner lining of the uterus. In a biopsy, the tissues from the inner lining of the uterus of the patient are taken and tested using the biomarkers for the presence of endometriosis. Endometriosis is an incurable disease and relapses after the primary treatment. Currently, the treatment options for endometriosis include the usage of hormone therapy and analgesics to control the disease.

TechNavio's analysts forecast the Global Endometriosis market will grow at a CAGR of 2.86 percent over the period 2013-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Endometriosis market for the period 2013-2018. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of endometriosis that are available in the market.

TechNavio's report, the Global Endometriosis Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, EMEA, and APAC regions; it also covers the Global Endometriosis market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • EMEA
  • APAC

Key Vendors

  • Abbvie Inc.
  • AstraZeneca plc
  • Bayer AG
  • Pfizer Inc.

Other Prominent Vendors

  • Astellas Pharma Inc.
  • Abbvie Inc.
  • Repros Therapeutics Inc.
  • Sanofi SA
  • Takeda Pharmaceuticals Co. Ltd.

Key Market Driver

  • High Unmet Needs in the Market

For a full, detailed list, view our report.

Key Market Challenge

  • Patent Expiries of Approved Drugs

For a full, detailed list, view our report.

Key Market Trend

  • Expected Launch of High-cost Therapies

For a full, detailed list, view our report.

Key questions answered in this report:

  • What will the market size be in 2018 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings
    • 03.2.1. Product Profiles

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Market Landscape

  • 06.1. Market Overview
  • 06.2. Market Size and Forecast
  • 06.3. Five Forces Analysis

07. Rate of Incidence and Prevalence

08. Market Segmentation by Type of Therapy

  • 08.1.1. Hormone Therapy
  • 08.1.2. Analgesics

09. Market Segmentation by Route of Administration and Type of Dosage Form

  • 09.1.1. Oral
  • 09.1.2. Parenteral
  • 09.1.3. Topical

10. Pipeline Portfolio

11. Geographical Segmentation

12. Buying Criteria

13. Market Growth Drivers

14. Drivers and their Impact

15. Market Challenges

16. Impact of Drivers and Challenges

17. Market Trends

18. Trends and their Impact

19. Vendor Landscape

  • 19.1. Competitive Scenario
  • 19.1.1. Key News
  • 19.2. Market Share Analysis 2013
  • 19.3. Other Vendors

20. Key Vendor Analysis

  • 20.1. AbbVie Inc.
    • 20.1.1. Key Facts
    • 20.1.2. Business Description
    • 20.1.3. Product Segmentation
    • 20.1.4. Revenue by Product Line
    • 20.1.5. Revenue Comparison 2012 and 2013
    • 20.1.6. Revenue by Geographical Segmentation
    • 20.1.7. Business Strategy
    • 20.1.8. Key Developments
    • 20.1.9. SWOT Analysis
    • 20.1.10. Strengths
    • 20.1.11. Weaknesses
    • 20.1.12. Opportunities
    • 20.1.13. Threats
  • 20.2. AstraZeneca plc
    • 20.2.1. Key Facts
    • 20.2.2. Business Overview
    • 20.2.3. Business Segmentation
    • 20.2.4. Business Strategy
    • 20.2.5. Revenue by Business Segmentation
    • 20.2.6. Revenue Comparison 2011-2013
    • 20.2.7. Sales by Geography
    • 20.2.8. Key Developments
    • 20.2.9. SWOT Analysis
    • 20.2.10. Strengths
    • 20.2.11. Weaknesses
    • 20.2.12. Opportunities
    • 20.2.13. Threats
  • 20.3. Bayer AG
    • 20.3.1. Key Facts
    • 20.3.2. Business Overview
    • 20.3.3. Business Segmentation
    • 20.3.4. Business Strategy
    • 20.3.5. Sales Segmentation by Business
    • 20.3.6. Sales by Geographical Segmentation
    • 20.3.7. Key Information
    • 20.3.8. SWOT Analysis
    • 20.3.9. Strengths
    • 20.3.10. Weaknesses
    • 20.3.11. Opportunities
    • 20.3.12. Threats
  • 20.4. Pfizer Inc.
    • 20.4.1. Key Facts
    • 20.4.2. Business Overview
    • 20.4.3. Business Segmentation by Revenue 2013
    • 20.4.4. Business Segmentation by Revenue 2012 and 2013
    • 20.4.5. Sales by Geography
    • 20.4.6. Business Strategy
    • 20.4.7. Key Developments
    • 20.4.8. SWOT Analysis
    • 20.4.9. Strengths
    • 20.4.10. Weaknesses
    • 20.4.11. Opportunities
    • 20.4.12. Threats

21. Other Reports in this Series

List of Exhibits:

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Global Endometriosis Market 2013-2018 (US$ million)
  • Exhibit 3: Global Endometriosis Market by Type of Therapy
  • Exhibit 4: Global Endometriosis Market Segmentation by Type of Therapy 2013
  • Exhibit 5: Global Endometriosis Market by Route of Administration and Type of Dosage Form
  • Exhibit 6: Pipeline Portfolio of the Drugs for Endometriosis
  • Exhibit 7: Global Endometriosis Market by Geographical Segmentation 2013
  • Exhibit 8: AbbVie Inc.: Product Segmentation
  • Exhibit 9: AbbVie Inc.: Revenue by Product Line 2013
  • Exhibit 10: AbbVie Inc.: Revenue Comparison by Product Line 2012 and 2013 (US$ billion)
  • Exhibit 11: AbbVie Inc.: Revenue by Geographical Segmentation 2013
  • Exhibit 12: AstraZeneca plc: Business Segmentation
  • Exhibit 13: AstraZeneca plc: Business Segmentation by Revenue 2013
  • Exhibit 14: AstraZeneca plc: Business Segmentation by Revenue 2011-2013 (US$ billion)
  • Exhibit 15: AstraZeneca plc: Sales by Geography 2013
  • Exhibit 16: Business Segmentation of Bayer AG 2013
  • Exhibit 17: Sales Comparison of Bayer AG by Business Segment 2012 and 2013 (US$ million)
  • Exhibit 18: Sales Segmentation of Bayer AG by Geography 2013
  • Exhibit 19: Pfizer Inc.: Business Segmentation by Revenue 2013
  • Exhibit 20: Pfizer Inc.: Business Segmentation by Revenue 2012 and 2013
  • Exhibit 21: Pfizer Inc.: Sales by Geography 2013
Back to Top